PriceTargets.com logo

Gemini Therapeutics - GMTX Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$65.00 As of 12/17/2024 01:00 AM ET
▼ -1.18 (-1.78%)

This chart shows the closing price for GMTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Gemini Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GMTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GMTX

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Gemini Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $65.00.

This chart shows the closing price for GMTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Gemini Therapeutics. This rating has held steady since February 2023, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/27/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/23/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/19/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/18/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/18/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/11/2022HC WainwrightDowngradeBuy ➝ Neutral$5.00 ➝ $2.00
3/3/2022Leerink PartnersDowngradeOutperform ➝ Market Perform$10.00 ➝ $2.00
3/1/2022HC WainwrightLower Target$20.00 ➝ $5.00
3/1/2022Jefferies Financial GroupDowngradeBuy ➝ Hold$23.00 ➝ $1.50
1/24/2022Leerink PartnersLower TargetOutperform$15.00 ➝ $10.00
12/20/2021Leerink PartnersLower TargetOutperform$25.00 ➝ $15.00
12/15/2021HC WainwrightInitiated CoverageBuy$20.00
11/22/2021Stifel NicolausLower TargetBuy$20.00 ➝ $11.00
10/6/2021The Goldman Sachs GroupLower TargetBuy$20.00 ➝ $18.00
9/12/2021Leerink PartnersReiterated RatingBuy
4/8/2021Leerink PartnersInitiated CoverageOutperform$25.00
3/3/2021Jefferies Financial GroupInitiated CoverageBuy$23.00
3/2/2021The Goldman Sachs GroupInitiated CoverageBuy$20.00
2/16/2021Stifel NicolausInitiated CoverageBuy$20.00
(Data available from 12/18/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/22/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/21/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/20/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/19/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/19/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/18/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/18/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Gemini Therapeutics logo
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $65.00
Low: $64.65
High: $66.90

50 Day Range

MA: $57.49
Low: $44.82
High: $67.47

52 Week Range

Now: $65.00
Low: $1.16
High: $14.10

Volume

255,896 shs

Average Volume

189,291 shs

Market Capitalization

$2.82 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Gemini Therapeutics?

The following Wall Street analysts have issued stock ratings on Gemini Therapeutics in the last twelve months:
View the latest analyst ratings for GMTX.

What is the current price target for Gemini Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Gemini Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Gemini Therapeutics in the next year.
View the latest price targets for GMTX.

What is the current consensus analyst rating for Gemini Therapeutics?

Gemini Therapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for GMTX.

What other companies compete with Gemini Therapeutics?

Other companies that are similar to Gemini Therapeutics include Qiagen, Intra-Cellular Therapies, Roivant Sciences, Ascendis Pharma A/S and Revolution Medicines. Learn More about companies similar to Gemini Therapeutics.

How do I contact Gemini Therapeutics' investor relations team?

Gemini Therapeutics' physical mailing address is C/O FORESITE CAPITAL 600 MONTGOMERY ST SUITE 4500, SAN FRANCISCO CA, 94111. The company's listed phone number is 415-877-4887 and its investor relations email address is [email protected]. The official website for Gemini Therapeutics is www.geminitherapeutics.com. Learn More about contacing Gemini Therapeutics investor relations.